Strafford will be offering a webinar entitled "Patent Exclusivity Health Checks for Biologics: Are Your U.S. Patents Ready to Maximize ROI?" on May 17, 2018 from 1:00 to 2:30 pm (EDT). M. Paul Barker, Steven P. O’Connor, and Sanya Sukduang of Finnegan Henderson Farabow Garrett & Dunner will guide patent counsel on the essentials of patent exclusivity that are in critical need of independent checking, and discuss crucial health checks on U.S. patent exclusivity for biologics in Phase II efficacy trials and proceedings through large scale randomized Phase III clinical trials, submission of the BLA, and subsequent approval and marketing. The webinar will review the following issues:
• How should counsel respond if a health check uncovers sub-optimal protection or defects in a patent claim?
• Are the BCPIA claims definite or enabled under the current standards?
• Is there a need for supplemental examination to clear the path to enforceability?
The registration fee for the webcast is $297. Those interested in registering for the webinar, can do so here.
Comments